Gemcitabine plus erlotinib (GE) followed by capecitabine (C) versus capecitabine plus erlotinib (CE) followed by gemcitabine (G) in advanced pancreatic cancer (APC): A randomized, cross-over phase III trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

被引：15

作者：

Boeck, S. H.

Vehling-Kaiser, U.

Waldschmidt, D.

Kettner, E.

Maerten, A.

Winkelmann, C.

Klein, S.

Kojouharoff, G.

Jung, A.

Heinemann, V.

机构：

[1] Univ Munich, Klinikum Grosshadern, Dept Internal Med 3, D-80539 Munich, Germany

[2] Univ Cologne, Dept Gastroenterol & Hepatol, D-50931 Cologne, Germany

[3] Klinikum Magdeburg, Dept Hematol Oncol, Magdeburg, Germany

[4] Heidelberg Univ, Dept Surg, Heidelberg, Germany

[5] Krankenhaus Lutherstadt Wittenberg, Dept Internal Med, Lutherstadt Wittenberg, Germany

[6] Klinikum Bayreuth, Dept Internal Med 4, Bayreuth, Germany

[7] Univ Munich, Dept Pathol, Munich, Germany

[8] Univ Munich, Klinikum Grosshadern, Dept Med Oncol, D-80539 Munich, Germany

来源：

关键词：

D O I：

10.1200/jco.2010.28.18_suppl.lba4011

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA4011

引用

页数：1